BTK Inhibitors in B-Cell Malignancies: Expert Perspectives to Guide Clinical Decisions

Review key strategies for integrating BTK inhibition into management of your patients with B-cell malignancies with downloadable slides from a live expert-led meeting series.

Share

Program Content

No activities added yet

Supporters

Supported by educational grants from

AstraZeneca

BeiGene, Ltd.

Janssen administered by Scientific Affairs